Phentolamine mesylate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for phentolamine mesylate and what is the scope of patent protection?
Phentolamine mesylate
is the generic ingredient in three branded drugs marketed by Septodont Holding, Hikma, Precision Dose Inc, and Novartis, and is included in four NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Phentolamine mesylate has sixteen patent family members in twelve countries.
There are three drug master file entries for phentolamine mesylate. Four suppliers are listed for this compound.
Summary for phentolamine mesylate
International Patents: | 16 |
US Patents: | 3 |
Tradenames: | 3 |
Applicants: | 4 |
NDAs: | 4 |
Drug Master File Entries: | 3 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 106 |
Clinical Trials: | 15 |
Patent Applications: | 1,566 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for phentolamine mesylate |
What excipients (inactive ingredients) are in phentolamine mesylate? | phentolamine mesylate excipients list |
DailyMed Link: | phentolamine mesylate at DailyMed |
Recent Clinical Trials for phentolamine mesylate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 3 |
University of Alberta | N/A |
University of Missouri-Columbia | Early Phase 1 |
Pharmacology for phentolamine mesylate
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for phentolamine mesylate
US Patents and Regulatory Information for phentolamine mesylate
Expired US Patents for phentolamine mesylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | See Plans and Pricing | See Plans and Pricing |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for phentolamine mesylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | PA04012507 | FORMULACIONES ESTABILIZADAS PARA ANTOAGONISTAS DEL RECEPTOR ALFA-ADRENERGICO Y USOS DE LAS MISMAS. (STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF.) | See Plans and Pricing |
Israel | 165599 | תכשירים נוזליים יציבים המכילים אנטגוניסט לקולטן אלפא אדרנרגי במינון נמוך ושימושים בהם (Stable liquid compositions comprising a low dose alpha adrenergic receptor antagonist and uses thereof) | See Plans and Pricing |
Brazil | 0311965 | Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos | See Plans and Pricing |
Japan | 2005533869 | See Plans and Pricing | |
Japan | 2010280702 | STABILIZED FORMULATION OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USE THEREOF | See Plans and Pricing |
Australia | 2003247568 | STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.